Patents by Inventor Samuel C. Silverstein
Samuel C. Silverstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10912798Abstract: A method is provided, inter alia, for treating a subject suffering from an infectious or neoplastic disease with immunotherapy. The method includes determining the critical concentration of immune cells required to treat or eradicate an infectious or neoplastic disease in the subject using an in vitro assay of the present invention; and administering to the subject the critical concentration of immune cells determined in the assay.Type: GrantFiled: October 9, 2018Date of Patent: February 9, 2021Assignee: The Trustees of Columbia University in the City of New YorkInventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter Lee
-
Publication number: 20190038673Abstract: An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8+ T-cell on a sensitized melanoma cell. A method for improving the specific cytolytic activity (SCA) of an immune cell comprising contacting an immune cell with an antigen and an antigen-independent pro-inflammatory agent is provided. A method for ex vivo expansion of antigen-specific CD8+ T-cells with enhanced specific cytolytic activity (SCA) comprising culturing the antigen-specific CD8+ T-cells in a suitable culture media comprising an amino acid. An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. A method of treating a subject suffering from an infectious or neoplastic disease with immuno therapy is described.Type: ApplicationFiled: October 9, 2018Publication date: February 7, 2019Inventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter Lee
-
Patent number: 10137153Abstract: A method is provided for treating a subject suffering from an infectious or neoplastic disease with immunotherapy. The method comprises determining the critical concentration of immune cells required to treat or eradicate an infectious or neoplastic disease in the subject using an in vitro assay of the present invention; and administering to the subject the critical concentration of immune cells determined in the assay.Type: GrantFiled: November 7, 2016Date of Patent: November 27, 2018Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter Lee
-
Publication number: 20170106022Abstract: An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8+ T-cell on a sensitized melanoma cell. A method for improving the specific cytolytic activity (SCA) of an immune cell comprising contacting an immune cell with an antigen and an antigen-independent pro-inflammatory agent is provided. A method for ex vivo expansion of antigen-specific CD8+ T-cells with enhanced specific cytolytic activity (SCA) comprising culturing the antigen-specific CD8+ T-cells in a suitable culture media comprising an amino acid. An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. A method of treating a subject suffering from an infectious or neoplastic disease with immuno therapy is described.Type: ApplicationFiled: November 7, 2016Publication date: April 20, 2017Inventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter Lee
-
Patent number: 9488644Abstract: An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8+ T-cell on a sensitized melanoma cell. A method for improving the specific cytolytic activity (SCA) of an immune cell comprising contacting an immune cell with an antigen and an antigen-independent pro-inflammatory agent is provided. A method for ex vivo expansion of antigen-specific CD8+ T-cells with enhanced specific cytolytic activity (SCA) comprising culturing the antigen-specific CD8+ T-cells in a suitable culture media comprising an amino acid. An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. A method of treating a subject suffering from an infectious or neoplastic disease with immuno therapy is described.Type: GrantFiled: November 11, 2010Date of Patent: November 8, 2016Assignee: The Trustees of Columbia University in the City of New YorkInventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter P. Lee
-
Publication number: 20130064802Abstract: An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. Also provided is an in vitro assay for determining the effect of an activated CD8+ T-cell on a sensitized melanoma cell. A method for improving the specific cytolytic activity (SCA) of an immune cell comprising contacting an immune cell with an antigen and an antigen-independent pro-inflammatory agent is provided. A method for ex vivo expansion of antigen-specific CD8+ T-cells with enhanced specific cytolytic activity (SCA) comprising culturing the antigen-specific CD8+ T-cells in a suitable culture media comprising an amino acid. An in vitro assay is provided for determining the effect of an immune cell on a cell from an infectious or neoplastic disease. A method of treating a subject suffering from an infectious or neoplastic disease with immuno therapy is described.Type: ApplicationFiled: November 11, 2010Publication date: March 14, 2013Inventors: Samuel C. Silverstein, John D. Loike, Sadna Budhu, Peter Lee
-
Patent number: 7132096Abstract: The present invention provides methods for inhibiting growth of a bacterium which consists essentially of contacting the bacterium with gemfibrozil, or a related compound, in a concentration effective to inhibit growth of the bacterium. This invention also provides related screening and therapeutic methods.Type: GrantFiled: March 29, 2004Date of Patent: November 7, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: Christina Kabbash, Howard A. Shuman, Samuel C. Silverstein, Phyllis Della-Latta
-
Patent number: 7037500Abstract: This invention provides methods of delivering an antigen to an Class I or Class II MHC receptors to induce immunity against the antigen in a subject having a disease. This invention also provides methods of delivering an antigen to an Class II or class I MHC receptor to supress immunity against the antigen in a subject having a disease.Type: GrantFiled: September 8, 2000Date of Patent: May 2, 2006Assignee: The Trustees of Columbia University in the City of New YorkInventors: Samuel C. Silverstein, John D. Loike, Francesco DiVirgilio
-
Patent number: 6881553Abstract: The present invention provides a method of selecting a compound which inhibits the enzymatic activity of enoyl reductase which comprises: (A) contacting enoyl reductase with the compound linked to an acyl carrier protein; (B) measuring the enzymatic activity of the enoyl reductase of step (A) compared with the enzymatic activity of enoyl reductase in the absence of the compound and selecting the compound which inhibits the enzymatic activity of enoyl reductase.Type: GrantFiled: February 13, 2003Date of Patent: April 19, 2005Assignees: The Trustees of Columbia University in the City of New York, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Christina Kabbash, Samuel C. Silverstein, Howard A. Shuman, John S. Blanchard
-
Publication number: 20040266838Abstract: The present invention provides for a method for inhibiting growth of a bacterium which consists essentially of contacting the bacterium with a compound having the structure: 1Type: ApplicationFiled: March 29, 2004Publication date: December 30, 2004Applicant: The Trustees of Columbia University in the City of New YorkInventors: Christina Kabbash, Howard A. Shuman, Samuel C. Silverstein, Phyllis Della- Latta
-
Patent number: 6713043Abstract: The present invention provides for a method for inhibiting growth of a bacterium which consists essentially of contacting the bacterium with a compound having the structure: wherein each of R1, R2, R3, R4, R5 and R6 may be independently H, F, Cl, Br, I, —OH, —OR7, —CN, —COR7, —SR7, —N(R7)2, —NR7COR8, —NO2, —(CH2)pOR7, —(CH2)pX(R7)2, —(CH2)pXR7COR8, a straight chain or branched, substituted or unsubstituted C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, C3-C10 cycloalkyl, C3-C10 cycloalkenyl, thioalkyl, methylene thioalkyl, acyl, phenyl, substituted phenyl, or heteroaryl; wherein a linkage to the benzene ring may alternatively be —N—, —S-—, —O— or —C—; wherein R7 or R8 may be independently H, F, Cl, Br, I, —OH, —CN, —COH, —SH2, —NH2, —NHCOH, —(CH2)pOH, —(CH2)pX(CH2), —(CH2)pXCOH, a straight chain or branched, substituted or unsuType: GrantFiled: February 29, 1996Date of Patent: March 30, 2004Assignee: The Trustees of Columbia University in the City of New YorkInventors: Christina Kabbash, Howard A. Shuman, Samuel C. Silverstein, Phyllis Della-Latta
-
Publication number: 20030191146Abstract: The present invention provides for a method of inhibiting activity of an enoyl reductase enzyme in a cell which comprises contacting the cell with a compound having the structure: 1Type: ApplicationFiled: February 13, 2003Publication date: October 9, 2003Applicant: The Trustees of Columbia University in the City of New YorkInventors: Christina Kabbash, Samuel C. Silverstein, Howard A. Shuman, John S. Blanchard
-
Publication number: 20030100042Abstract: The present invention provides for a method for inhibiting growth of a bacterium which consists essentially of contacting the bacterium with a compound having the structure: 1Type: ApplicationFiled: February 29, 1996Publication date: May 29, 2003Inventors: CHRISTINA KABBASH, HOWARD A. SHUMAN, SAMUEL C. SILVERSTEIN, PHYLLIS DELLA-LATTA
-
Patent number: 6531291Abstract: The present invention provides a method of selecting a compound which inhibits the enzymatic activity of enoyl reductase which comprises: (A) contacting enoyl reductase with the compound linked to an acyl carrier protein; (B) measuring the enzymatic activity of the entoy reductase of step (A) compared with the enzymatic activity of enoyl reductase in the absence of the compound and selecting the compound which inhibits the enzymatic activity of enoyl reductase.Type: GrantFiled: November 10, 1999Date of Patent: March 11, 2003Assignees: The Trustees of Columbia University in the City of New York, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Christina Kabbash, Samuel C. Silverstein, Howard A. Shuman, John S. Blanchard
-
Publication number: 20020114804Abstract: An agent capable of inhibiting signalling mediated by a &bgr;1 integrin cell surface receptor of leukocyte cells will treat a bacterial infection associated with a surface of a foreign body over and around which fibrin has been deposited, or a malignant tumor over and around which tenascin has been deposited. In addition, coating a foreign body with a fibrinolytic agent will prevent chronic bacterial infection associated with the surface of the foreign body. Furthermore, an agent capable of stimulating signalling mediated by a &bgr;1 integrin cell surface receptor of leukocyte cells will treat chronic inflammation.Type: ApplicationFiled: October 22, 1998Publication date: August 22, 2002Inventors: JOHN LOIKE, SAMUEL C. SILVERSTEIN
-
Patent number: 5843436Abstract: An agent capable of inhibiting signalling mediated by a .beta..sub.1 integrin cell surface receptor of leukocyte cells will treat a bacterial infection associated with a surface of a foreign body over and around which fibrin has been deposited, or a malignant tumor over and around which tenascin has been deposited. In addition, coating a foreign body with a fibrinolytic agent will prevent chronic bacterial infection associated with the surface of the foreign body. Furthermore, an agent capable of stimulating signalling mediated by a .beta..sub.1 integrin cell surface receptor of leukocyte cells will treat chronic inflammation.Type: GrantFiled: April 22, 1996Date of Patent: December 1, 1998Assignee: The Trustees of Columbia University, in the City of New YorkInventors: John Loike, Samuel C. Silverstein
-
Patent number: 5422372Abstract: This invention provides an improved therapeutic method which comprises administering to a mammal a therapeutic agent and 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid, or a structural analog thereof, in an amount effective to improve the efficacy of the therapeutic agent. Also provided by this invention is an improved therapeutic method which comprises administering to a mammal a therapeutic agent and 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid, or a structural analog thereof, in an amount effective to improve the efficacy of the therapeutic agent. Further provided by this invention is a method of treating an intracellular bacterial infection which comprises contacting the infected cell with an effective amount of a therapeutic agent and with an effective amount of 5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid, or a structural analog therof, effective to treat an intracellular bacterial infection.Type: GrantFiled: June 15, 1993Date of Patent: June 6, 1995Assignee: The Trustees of Columbia University in the City of New YorkInventors: Samuel C. Silverstein, Harold C. Neu, Charles Cao